Table 1. Characteristics of included studies.

Study	Year	Number		Mean age	Intervention		Duration	Outcomes
		experiment	control	(years)	experiment	control	(weeks)
					(mg/day)	(mg/day)
Yang J et al.29	2012	30	30	50.7	0.5	ADV 10	48	A/B/C/D/E
			30	UC		LAM 100	48	A/B/C/D/E
			30	UC		CT	48	A/B/C/D/E
Lin XS et al.23	2011	32	32	49.7	0.5	CT	72	A/E/F
Ren WX et al.30	2014	27	27	48	0.5	CT	48	A/B/D/E
Luo HB et al.31	2009	48	48	54.9	0.5	CT	48	A/B
Ning ZH et al.32	2009	37	38	47.5	0.5	CT	24	A/B/F
Han ZQ et al.24	2009	30	30	56.2	0.5	CT	24	A/B/D/E/F
Chen FZ et al.16	2010	26	26	48.5	0.5	LAM 100	48	A/B/F
Zhang FL33	2011	28	26	45.6	0.5	CT	24	A/B/D
Zhang RL34	2010	18	18	UC	0.5	CT	24	A/B/E/F
Guo YM et al.35	2014	42	42	UC	0.5	CT	24	A/B/D/E
Yang J et al.9	2012	40	40	46.6	0.5	ADV 10	48	A/B/E/F
Li H36	2009	20	20	UC	0.5	CT	24	A/B/D/E
Xu Y22	2013	43	43	50.1	0.5	LDT 600 and ADV10	48	A/B/D
Feng J et al.37	2008	22	25	UC	0.5	LAM 100	48	A/B/D/F
			25	UC		ADV10	48	A/B/D/F
			24	UC		CT	48	A/B/D/F
Zhang DH et al.18	2011	27	27	UC	0.5	LAM 100	48	A/B/D/F
			27	UC		ADV 10	48	A/B/D/F
			24	UC		CT	48	A/B/D/F
Liaw et al.8	2011	100	91	51	1	ADV 10	96	A/B/F
Liaw yf et al.13	2011	22	45	54	0.5or1	TDF 300	48	A/B/F
Yang L38	2015	40	40	UC	0.5	LAM 100	48	C/E
Gulizire•Maola39	2015	35	35	UC	0.5	CT	48	A/B/C/D
Hu XM19	2014	36	36	46.5	0.5	LAM 100	1 year	A/B/C/F
Zhang J40	2014	27	27	UC	0.5	CT	48	A/B
Zhao ZY41	2014	36	36	UC	0.5	CT	48	A/B/E
Li MX42	2014	48	48	UC	0.5	CT	48	A/B/G
Zhou XL et al.43	2015	44	44	UC	0.5	CT	24	A/B/C/E
Bi YL20	2014	43	48	UC	0.5	LAM 100 and ADV 10	48	A/B/C/D
Shao JB et al.21	2010	29	28	43.6	0.5	LAM 100	96	A/E

UC: unclear; CT: comprehensive therapy (patients who did not use any NAs); A: HBV DNA; B: Hepatic function; C: Adverse Drug Reaction; D: Mortality; E: Child-pugh; F: HBeAg seroconversion; G: hepatitis B virus mutation rate.